Emyria Limited
Emyria Limited
Your view on EMD.AX
Overview
What the company does, where it operates, and who runs it.
About Emyria Limited
- Industry
- Medical - Healthcare Information Services
- Sector
- Healthcare
- CEO
- Gregory Hutchinson
- Headquarters
- D2, 661 Newcastle Street, Leederville, WA, AU
- Industry
- Medical - Healthcare Information Services
- Sector
- Healthcare
- CEO
- Gregory Hutchinson
- Headquarters
- D2, 661 Newcastle Street, Leederville, WA, AU
Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuticals, alongside an initiative for discovering new MDMA-based drugs.
Among its pipeline, EMD-RX5 is being explored for psychological distress and irritable bowel syndrome, while EMD-RX7 targets a variety of medical conditions. Established in 2018 and based in Leederville, Australia, the company adopted its current name, Emyria Limited, in September 2020, having previously operated as Emerald Clinics Limited.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Emyria Limited. Starting points for Emyria Limited: EPS -AUD 0.0076, beta 0.03 — an Medical - Healthcare Information Services name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Emyria Limited. Emyria Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Emyria Limited. Trailing twelve-month EPS for Emyria Limited stands at -AUD 0.0076. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|
| Average estimate | −AUD 0.01 | −AUD 0.01 |
| Lowest estimate | −AUD 0.01 | −AUD 0.01 |
| Highest estimate | −AUD 0.01 | −AUD 0.01 |
| Number of analysts | 1 | 1 |
| A year ago | −AUD 0.011 | — |
| Growth vs a year ago | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|
| Average estimate | AUD 9.70M | AUD 19.40M |
| Lowest estimate | AUD 9.70M | AUD 19.40M |
| Highest estimate | AUD 9.70M | AUD 19.40M |
| Number of analysts | 1 | 1 |
| A year ago | AUD 3.88M | — |
| Growth vs a year ago | +150.0% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Emyria Limited. Emyria Limited has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ADO.AXAnteoTech Limited | Basic Materials | Chemicals - Specialty | — | ||
| AGN.AXArgenica Therapeutics Ltd | Healthcare | Biotechnology | — | ||
| BDX.AXBCAL Diagnostics Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| DOC.AXDoctor Care Anywhere Group PLC | Healthcare | Medical - Healthcare Information Services | — | ||
| EYE.AXNova Eye Medical Limited | Healthcare | Medical - Devices | — | ||
| IIQ.AXINOVIQ Ltd | Healthcare | Medical - Diagnostics & Research | — | ||
| LGP.AXLittle Green Pharma Ltd | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| MAP.AXMicroba Life Sciences Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| EKGGFCardioComm Solutions, Inc. | Healthcare | OTC | $1.4M | ||
| EMYSFEasy Technologies Inc. | Healthcare | OTC | $142,220 | ||
| ENL.AXEnlitic, Inc. | Healthcare | ASX | — | ||
| EVHEvolent Health, Inc. | Healthcare | NYSE | $442.1M | ||
| EWLLeWellness Healthcare Corporation | Healthcare | OTC | $185,077 | ||
| FRLIFrélii, Inc. | Healthcare | OTC | $5,347 | ||
| GDRXGoodRx Holdings, Inc. | Healthcare | NASDAQ | $1.1B | ||
| HCATHealth Catalyst, Inc. | Healthcare | NASDAQ | $98.2M | ||
| HCTIHealthcare Triangle, Inc. | Healthcare | NASDAQ | $2.4M | ||
| HDVYHealth Discovery Corporation | Healthcare | OTC | $41,171 | ||
| HIQ.AXHITIQ Limited | Healthcare | ASX | — | ||
| HNGEHinge Health, Inc. | Healthcare | NYSE | $9.3B | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Emyria Limited. Coverage tracks Emyria Limited within Medical - Healthcare Information Services (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Emyria Limited.